Release of markedly increased quantities of prostaglandin D2 in humans following the administration of nicotinic acid
References (18)
- et al.
Fifteen year mortality in coronary drug project patients: long-term benefit with niacin
J. Am. Coll. Cardiol.
(1986) - et al.
Prostacyclin production augmented in the short term by nicotinic acid
Lancet
(1983) - et al.
A double blind placebo controlled evaluation of prostacyclin in man
Life Sci.
(1979) Nicotinic acid and its derivatives: A short survey
Adv. Lipid Res.
(1983)- et al.
- et al.
Studies on the mechanism of flush induced by nicotinic acid
Acta pharmacol et toxicol
(1977) Carcinoid syndrome and disorders of systemic mastcell activation including systemic mastocytosis
Endocr. Metab. Clin. North Am.
(1988)- et al.
Mastocytosis without urticaria pigmentosa: A frequently unrecognized cause of recurrent syncope
Trans. Assoc. Am. Phys.
(1982) - et al.
Increased production of prostaglandin D2 in patients with systemic mastocytosis
New Engl. J. Med.
(1980)
Cited by (201)
Nontryptase Urinary and Hematologic Biomarkers of Mast Cell Expansion and Mast Cell Activation: Status 2022
2022, Journal of Allergy and Clinical Immunology: In PracticeCitation Excerpt :Addition of aspirin (975 mg 4 times daily) to the antihistamine program resulted in a decreased excretion of this PGD2 metabolite by 80% to 85% and a cessation of flushing and hypotension in patient 2.13 Following the discovery that aspirin inhibits nicotinic acid–induced flushing,40 subsequent reports documented contemporaneous flush-associated increased plasma levels of 9α,11β-PGF2 in these patients.41 The skin was identified as the major site of PGD2 release after topical application of methylnicotinate (10−1 mol) with plasma levels of 9α,11β-PGF2 rising 25- to 33-fold.42
The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome
2020, Journal of Allergy and Clinical Immunology: In PracticeNicotinic acid transport into human liver involves organic anion transporter 2 (SLC22A7)
2020, Biochemical PharmacologyThe microvascular response in the skin to topical application of methyl nicotinate: Effect of concentration and variation between skin sites
2019, Microvascular ResearchCitation Excerpt :Methyl nicotinate (MN) is a nicotinic acid, which induces a local cutaneous erythema when topically applied to the skin. The physiologically active compound is the methyl ester of nicotinate, commonly known as the B vitamin niacin (Morrow et al., 1989). Its rubefacient effect is related to a transient increase in the microcirculatory perfusion, which is hypothesized to be mediated through the prostaglandin D2 (PGD2) pathway (Morrow et al., 1989).
Methylnicotinate stimulated prostaglandin synthesis in patients with schizophrenia: A preliminary investigation
2018, Prostaglandins Leukotrienes and Essential Fatty AcidsA rapid UPLC-MS/MS assay for eicosanoids in human plasma: Application to evaluate niacin responsivity
2018, Prostaglandins Leukotrienes and Essential Fatty Acids